{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:06:40Z","timestamp":1794330400504,"version":"4.9.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.iliver.2024.100107","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T17:59:23Z","timestamp":1722275963000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Serum IP-10 increase correlated with PEG-IFN\u03b1 response in nucleot(s)ide analogs-treated patients with chronic hepatitis B"],"prefix":"10.1016","volume":"3","author":[{"given":"Wen-Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iliver.2024.100107_bib1","first-page":"435","article-title":"Chronic hepatitis B virus: what an internist needs to know: serologic diagnosis, treatment options, and hepatitis B virus reactivation","volume":"107","author":"Block","year":"2023","journal-title":"Med Clin"},{"issue":"10381","key":"10.1016\/j.iliver.2024.100107_bib2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iliver.2024.100107_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.iliver.2024.100107_bib4","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.iliver.2024.100107_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2024.100107_bib6","article-title":"Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-\u03b1 in NAs-suppressed chronic hepatitis B patients","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2024.100107_bib7","article-title":"Immune mechanisms underlying hepatitis B surface antigen seroclearance in chronic hepatitis B patients with viral coinfection","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.iliver.2024.100107_bib8","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.cmi.2015.03.003","article-title":"Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-\u03b3-induced protein 10 levels in HBV\/HCV-coinfected patients","volume":"21","author":"Wiegand","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.iliver.2024.100107_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2016.05.002","article-title":"Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir","volume":"131","author":"Willemse","year":"2016","journal-title":"Antivir Res"},{"issue":"1","key":"10.1016\/j.iliver.2024.100107_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/apt.13447","article-title":"Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B","volume":"43","author":"Wong","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.iliver.2024.100107_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","article-title":"A\u00a0longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B","volume":"52","author":"Tan","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2024.100107_bib12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.14348\/molcells.2017.0051","article-title":"IP-10 expression in patients with chronic HBV infection and its ability to predict the decrease in HBsAg levels after treatment with entecavir","volume":"40","author":"Zhao","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.iliver.2024.100107_bib13","article-title":"Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.iliver.2024.100107_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2013.01.029","article-title":"Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B","volume":"58","author":"Sonneveld","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.iliver.2024.100107_bib15","first-page":"769","article-title":"Guidelines for prevention and treatment of chronic hepatitis B","volume":"9","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2024.100107_bib16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: an expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.iliver.2024.100107_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2024.100107_bib18","first-page":"129","article-title":"Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"39","author":"Khlaiphuengsin","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"10.1016\/j.iliver.2024.100107_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.32400","article-title":"Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B","volume":"76","author":"Perrillo","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.iliver.2024.100107_bib20","first-page":"45","article-title":"Expression of CXC chemokine IP-10 in patients with chronic hepatitis B","volume":"7","author":"Wang","year":"2008","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"10.1016\/j.iliver.2024.100107_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12072-017-9803-4","article-title":"Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B","volume":"11","author":"Chen","year":"2017","journal-title":"Hepatol Int"},{"issue":"11\u201312","key":"10.1016\/j.iliver.2024.100107_bib22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17474124.2022.2156338","article-title":"Hepatitis B flare: the good, the bad and the ugly","volume":"16","author":"Liaw","year":"2022","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.iliver.2024.100107_bib23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277294782400032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277294782400032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:25:43Z","timestamp":1727450743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277294782400032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S277294782400032X"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2024.100107","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum IP-10 increase correlated with PEG-IFN\u03b1 response in nucleot(s)ide analogs-treated patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2024.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}